Nektar Therapeutics initiates clinical study of NKTR-358
Nektar Therapeutics announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new biologic therapy, which is being developed to treat a wide range of auto-immune diseases and inflammatory disorders. March 27, 2017